Placebo News and Research

RSS

Yoga as therapy in neuropsychiatric disorders

Yoga is commonly seen as a practice beneficial to body and mind. Increasingly, yoga is being taken a step further and applied as a form of complementary and alternative medicine in treating psychiatric disorders.

31 Aug 2011

Positive results from Bionovo's Menerba tolerability trial on menopausal hot flashes

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced the positive results from the completion of their tolerability trial of Menerba (MF101) for menopausal hot flashes.

31 Aug 2011

Positive results from Pearl's formoterol fumarate MDI Phase 2b trial on moderate-to-severe COPD

Pearl Therapeutics Inc. today announced positive results from a randomized, double-blind, Phase 2b, dose-ranging study of its formoterol fumarate metered dose inhaler (FF MDI; PT005), a long-acting beta-2 agonist (LABA) compared to placebo and Foradil Aerolizer in patients with moderate-to-severe COPD.

31 Aug 2011

FDA accepts Salix and Progenics' sNDA filing for RELISTOR to treat opioid-induced constipation

Progenics Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental New Drug Application (sNDA) for RELISTOR Subcutaneous Injection to treat opioid-induced constipation (OIC) in patients with non-cancer pain.

30 Aug 2011

ZIOPHARM initiates ZIN ATI-001 Phase 1 clinical study in advanced melanoma

ZIOPHARM Oncology, Inc. today announced that the first patient has been dosed in a Phase 1 clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate, in patients with advanced melanoma.

30 Aug 2011

Vitamin A supplements could save the lives of 600,000 children a year, researchers say

"Giving vitamin A supplements to children under the age of five in developing countries could save 600,000 lives a year, researchers claim" in a paper published Thursday in the British Medical Journal, BBC News reports.

30 Aug 2011

Results of darexaban phase II trial in recent acute coronary syndrome presented at ESC Congress

A phase II dose-finding study has found that the new oral Factor Xa inhibitor darexaban was associated with a two to four-fold increase in bleeding when added to dual antiplatelet therapy in patients following an acute coronary syndrome.

30 Aug 2011

Ivabradine reduces heart volume among patients with cardiac insufficiency

As guest speaker at the European Society of Cardiology's Congress currently under way in Paris, Dr. Jean-Claude Tardif, Director of the Montreal Heart Institute's Research Centre and professor of medicine at the Universit- de Montr-al, today presented the results of an analysis demonstrating that ivabradine, a medication used to reduce heart rate, also reduces heart volume (left ventricle) among patients with cardiac insufficiency.

30 Aug 2011

Vitamin A supplements in children could save up to 600,000 lives a year: Study

Researchers have found that giving vitamin A supplements to children under the age of five in developing countries could save up to 600,000 lives a year. Writing in the British Medical Journal, UK and Pakistani experts assessed 43 studies involving 200,000 children, and found deaths were cut by 24% if children were given the vitamin. They add that it would also cut rates of measles and diarrhea.

30 Aug 2011

Health Canada approves Bayer's STAXYN for treatment of erectile dysfunction

Today, Bayer Inc. announced the Health Canada approval of STAXYN, the first orally disintegrating tablet for the treatment of erectile dysfunction (ED) that lasts up to eight hours.

29 Aug 2011

Statins protect people against death from respiratory illness, infections

The death rate among patients prescribed a statin in a major trial that ended in 2003 is still lower than those given a placebo, even though most participants in both groups have been taking statins ever since. ASCOT, the Anglo-Scandinavian Cardiac Outcomes Trial, was stopped early because the statin was so effective at preventing heart attacks and strokes, but a new analysis has shown that eight years on, the most significant difference between the groups is a reduction in deaths from infection and respiratory illness.

29 Aug 2011

AAO-HNSF's 2011 Annual Meeting & OTO EXPO to convene in San Francisco

The 2011 Annual Meeting & OTO EXPO of the American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF), the largest meeting of ear, nose, and throat doctors in the world, will convene September 11-14, 2011, in San Francisco, CA.

29 Aug 2011

Colchicine more effective than placebo for recurrent pericarditis

Colchicine, when given in addition to conventional therapy, was more effective than placebo in reducing the incidence of recurrence and the persistence of symptoms of pericarditis in a randomised controlled trial.

29 Aug 2011

Astellas seeks regulatory approval for mirabegron to treat overactive bladder in the U.S., Europe

Astellas Pharma Inc. today announced the submission of a New Drug Application and Market Authorisation Application for mirabegron to the U.S. Food and Drug Administration and the European Medicines Agency.

29 Aug 2011

Azithromycin can help reduce wheezing, other acute symptoms of COPD

A common antibiotic can help reduce the severe wheezing and other acute symptoms of chronic obstructive pulmonary disease, according to a large, multicenter clinical trial sponsored by the National Institutes of Health and conducted at the University of California, San Francisco (UCSF).

29 Aug 2011

Nasal spray with hot chili pepper ingredient may help people clear up sinus inflammation

Hot chili peppers are known to make people "tear up," but a new study led by University of Cincinnati allergy researcher Jonathan Bernstein, MD, found that a nasal spray containing an ingredient derived from hot chili peppers (Capsicum annum) may help people "clear up" certain types of sinus inflammation.

26 Aug 2011

Firazyr receives FDA approval for treatment of HAE acute attacks

The U.S. Food and Drug Administration today approved Firazyr (icatibant) Injection for the treatment of acute attacks of a rare condition called hereditary angioedema (HAE) in people ages 18 years and older.

26 Aug 2011

Boehringer Ingelheim, Lilly receive EU approval for linagliptin to treat type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today received Marketing Authorization from the European Commission for linagliptin 5 mg film-coated tablets for the treatment of adults with type 2 diabetes.

26 Aug 2011

Shire receives FDA marketing approval for FIRAZYR to treat acute attacks of HAE

Shire plc, the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for FIRAZYR for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

26 Aug 2011

Allergan gets FDA nod for use of Botox in urinary incontinence

Allergan Inc. has received United States Food and Drug Administration (FDA) approval to market the wrinkle smoother Botox as a treatment for urinary incontinence. The FDA approved the drug for people with overactive bladders who have neurologic conditions such as multiple sclerosis and spinal cord injuries, the agency said today in a statement. The medicine is injected into the bladder to increase its capacity by relaxing muscles.

25 Aug 2011

Placebo News and Research

Yoga as therapy in neuropsychiatric disorders

Positive results from Bionovo's Menerba tolerability trial on menopausal hot flashes

Positive results from Pearl's formoterol fumarate MDI Phase 2b trial on moderate-to-severe COPD

FDA accepts Salix and Progenics' sNDA filing for RELISTOR to treat opioid-induced constipation

ZIOPHARM initiates ZIN ATI-001 Phase 1 clinical study in advanced melanoma

Vitamin A supplements could save the lives of 600,000 children a year, researchers say

Results of darexaban phase II trial in recent acute coronary syndrome presented at ESC Congress

Ivabradine reduces heart volume among patients with cardiac insufficiency

Vitamin A supplements in children could save up to 600,000 lives a year: Study

Health Canada approves Bayer's STAXYN for treatment of erectile dysfunction

Statins protect people against death from respiratory illness, infections

AAO-HNSF's 2011 Annual Meeting & OTO EXPO to convene in San Francisco

Colchicine more effective than placebo for recurrent pericarditis

Astellas seeks regulatory approval for mirabegron to treat overactive bladder in the U.S., Europe

Azithromycin can help reduce wheezing, other acute symptoms of COPD

Nasal spray with hot chili pepper ingredient may help people clear up sinus inflammation

Firazyr receives FDA approval for treatment of HAE acute attacks

Boehringer Ingelheim, Lilly receive EU approval for linagliptin to treat type 2 diabetes

Shire receives FDA marketing approval for FIRAZYR to treat acute attacks of HAE

Allergan gets FDA nod for use of Botox in urinary incontinence

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News